Trials / Completed
CompletedNCT00025233
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- National Cancer Institute (NCI) · NIH
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent cancer of the cervix. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.
Detailed description
OBJECTIVES: I. Determine the cytostatic antitumor activity of bevacizumab, in terms of 6-month progression-free survival (PFS), in patients with persistent or recurrent squamous cell carcinoma of the cervix. II. Determine the nature and degree of toxicity of this drug in these patients. III. Estimate the distribution of PFS and overall survival for patients treated with this drug. IV. Determine the frequency of clinical response (partial and complete) in patients treated with this drug. V. Determine the role of age and initial performance status as prognostic factors in patients treated with this drug. VI. Determine whether biological and imaging markers are associated with clinical efficacy of this drug, such as 6-month PFS, in these patients. OUTLINE: This is a multicenter study. Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study within 11-38 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | bevacizumab | Given IV |
| OTHER | laboratory biomarker analysis | Correlative studies |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2003-01-27
- Last updated
- 2019-07-24
- Results posted
- 2015-06-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00025233. Inclusion in this directory is not an endorsement.